SUMMARY Ninety patients randomly allocated to receive auranofin, matching placebo, or sodium aurothiomalate have been followed up for three years. Inefficacy led to cessation of treatment in 14 patients receiving auranofin, 27 receiving placebo, and one receiving sodium aurothiomalate. Twenty seven of the patients receiving placebo were reallocated within the study and 16 continued therapy at three years. This group showed similar statistically significant improvement in clinical and laboratory parameters at one, two, and three years to those on an active drug from the outset. Patients who discontinued auranofin because of inefficacy were offered sodium aurothiomalate therapy-eight patients in this group completed three years of treatment on sodium aurothiomalate and showed significant improvement in some but not all parameters. A hand radiograph erosion score showed a deterioration in 80% of patients remaining on auranofin, 75% of those on sodium aurothiomalate, and 80% of the original placebo group who continued an active drug for three years. Although more patients discontinued auranofin over the study period because of inefficacy, no difference could be shown between the degree of improvement in the subgroup who remained on auranofin and those receiving sodium aurothiomalate. No disadvantage in outcome could be shown for patients originally assigned to placebo.
It has been suggested that auranofin is less toxic than sodium aurothiomalate,l but controlled data about efficacy are needed to evaluate the role of this oral gold preparation in the management of rheumatoid arthritis. In addition, since long term therapy with a second line agent is necessary to demonstrate sustained benefit it is vital to continue with studies over several years, even when a drug has been shown to be effective in the short term.2 Of equal importance is prolonged meticulous monitoring to detect possible late toxicity.
The use of a placebo group in any study poses ethical problems and there is a need for careful follow up of patients originally assigned to placebo to ensure that no adverse outcome is apparent. This study was begun in 1980 and six month and one year results have previously been published. 3 
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report deals with a minimum of three years of follow up of patients receiving either sodium aurothiomalate or auranofin, or alternatively a minimum of three years after patients changed from placebo to one of these two active drugs. Data are also available on patients who discontinued auranofin and were reassigned to sodium aurothiomalate.
Patients and methods Ninety patients with definite or classical rheumatoid arthritis5 were enrolled in the study. No patient was receiving corticosteroids or had received these drugs for three months before the study, and similarly none had received another second line agent in the three months before the study. All continued nonsteroidal anti-inflamatory drugs, as necessary, throughout. All had active disease which required the addition of second line therapy because of failure to respond sufficiently to non-steroidal antiinflammatory drugs alone. 705 Overall, sodium aurothiomalate appears to be a more effective agent in the treatment of rheumatoid arthritis than auranofin, and the proportion of patients discontinuing the drug because of inefficacy is much higher with auranofin. The group of patients who found auranofin ineffective but then showed a response to sodium aurothiomalate lends further weight to the impression that auranofin is not such a powerful second line agent as injectable gold, but the numbers in this study are 
